Trials / Completed
CompletedNCT05395351
Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
Characteristics and In-hospital Outcomes of Chinese Elderly (>80 Years) Patients With Acute Ischemic Stroke Receiving Intravenous Recombinant Tissue Plasminogen Activator Treatment Within 4.5 Hours of Symptom Onset
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 113,035 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to find out the in-hospital clinical outcomes among Chinese Acute Ischaemic Stroke (AIS) patients, who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5 hours of symptom onset in different age groups (18 to 80 years and above 80 years).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rt-PA | Intravenous recombinant tissue plasminogen activator (IV rt-PA) |
Timeline
- Start date
- 2022-11-30
- Primary completion
- 2023-03-28
- Completion
- 2023-03-28
- First posted
- 2022-05-27
- Last updated
- 2024-12-20
- Results posted
- 2024-12-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05395351. Inclusion in this directory is not an endorsement.